Human umbilical cord mesenchymal stem cell-derived treatment of severe pulmonary arterial hypertension

Abstract Here we report application of human umbilical cord mesenchymal stem cell (HUCMSC)-derived therapy for pulmonary arterial hypertension (PAH). A 3-year-old female presented with heritable PAH associated hereditary hemorrhagic telangiectasia and was treated 6 months serial intravascular infusions conditioned media (CM) from allogenic HUCMSCs. The treatment markedly improved clinical hemodynamic parameters decreased blood plasma markers vascular fibrosis, injury inflammation. comparative analysis single-cell RNA sequencing data collected three HUCMSCs two vein endothelial (HUVEC) controls identified eight common clusters, all which indicated regenerative potential specific properties were validated by untargeted label-free quantitation the CM proteome, suggesting increased activity regeneration, autophagy anti-inflammation pathways mitochondrial function. Prostaglandin demonstrated HUCMSC secretion prostaglandin E2, known its capacity. Additional prospective studies are warranted to confirm further explore benefits HUCMSC-derived PAH.